Abstract

Despite advances of the last several years, treatments for HIV-1 infection and its complications are of limited benefit and duration. Reasons for the limited success of available drugs include the emergence of drug resistance, the development of dose- limiting toxicities, progressive increase in virus load, and progressive immunologic decline in the host. Nevertheless, it is essential to pursue clinical trials in individuals infected with HIV to test potentially useful drugs and because these trials offer the opportunity to examine the pathogenesis of HIV infection and disease progression. This application is a proposal for continued funding of the Adult AIDS Clinical Trials Unit (ACTU) at the University of Colorado Health Sciences Center in Denver, Colorado. We propose to continue enrolling HIV-infected individuals at all stages of disease into Phase I-III clinical trials to study the pathogenesis and treatment of HIV-1 infection and related opportunistic diseases. Specific emphasis will be placed on exploring the viral and immunologic basis for the pathogenesis of HIV disease in the context of experimental antiretroviral and immune-based therapies for HIV-1 infection. In addition, investigators from the Colorado ACTU will play important leadership roles in the AIDS Clinical Trials Group as a whole.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI032770-08
Application #
2856000
Study Section
Special Emphasis Panel (SRC (82))
Program Officer
Batzold, Frederick
Project Start
1992-03-01
Project End
1999-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045

  Publications

Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Gerber, John G; Kitch, Douglas W; Fichtenbaum, Carl J et al. (2008) Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 47:459-66
Sattler, Fred R; Rajicic, Natasa; Mulligan, Kathleen et al. (2008) Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. Am J Clin Nutr 88:1313-21
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Riddler, Sharon A; Jiang, Hongyu; Tenorio, Allan et al. (2007) A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 12:531-41
Margolis, David M; Mukherjee, A Lisa; Fletcher, Courtney V et al. (2007) The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS 21:2025-32
Fischl, Margaret A; Collier, Ann C; Mukherjee, A Lisa et al. (2007) Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS 21:325-33
Wilkin, Timothy J; Su, Zhaohui; Kuritzkes, Daniel R et al. (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 44:591-5

Showing the most recent 10 out of 55 publications